Loading organizations...
§ Private Profile · 99 Hayden Ave Ste 140, Lexington, Massachusetts 02421, US
Sentien Biotechnologies is a technology company.
Sentien Biotechnologies is a clinical-stage company focused on developing innovative cell therapies designed to restore balance to the immune system. The company’s core product, SBI-101, employs a unique blood conditioning approach that immobilizes Mesenchymal Stromal Cells within an extracorporeal device. This method allows for the sustained, controlled delivery of anti-inflammatory and regenerative factors, significantly enhancing the therapeutic potential of MSCs beyond traditional direct injection or intravenous infusion.
The company was founded by Biju Parekkadan, an accomplished biomedical engineer with affiliations including Harvard Stem Cell Institute. His foundational insight stemmed from the critical need to bridge academic research with tangible patient solutions, identifying a gap in effective delivery mechanisms for cell therapies to address severe systemic inflammatory conditions. Parekkadan established Sentien Biotechnologies to develop and translate these advanced therapeutic concepts into clinical reality.
Sentien Biotechnologies aims to provide improved treatment options for patients afflicted with systemic inflammatory diseases, including those suffering from sepsis-induced Acute Kidney Injury, a condition associated with high mortality and limited therapeutic alternatives. The company's vision is to transform how such diseases are treated by offering therapies that precisely modulate immune responses, thereby improving patient outcomes and quality of life for those facing debilitating inflammatory conditions.
Sentien Biotechnologies has raised $12.0M across 1 funding round.
Sentien Biotechnologies has raised $12.0M in total across 1 funding round.
Sentien Biotechnologies has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Series A in April 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2017 | $12M Series A | Mission BioCapital, Martin Heidecker | AMR Action Fund, Giacomo Chiesi, Mass Medical Angels, MBL Venture Capital | Announced |
Sentien Biotechnologies has raised $12.0M in total across 1 funding round.
Sentien Biotechnologies's investors include Mission BioCapital, Martin Heidecker, AMR Action Fund, Giacomo Chiesi, Mass Medical Angels, MBL Venture Capital.
# Sentien Biotechnologies: A Clinical-Stage Cell Therapy Company
Sentien Biotechnologies is not a technology company in the traditional sense, but rather a clinical-stage biotechnology firm developing novel cell therapies.[1] The company operates in the regenerative medicine and cell therapy space, focusing on treating patients with dysregulated immune systems and critical care diseases.
Sentien Biotechnologies develops cell-based therapies designed to restore immune system balance in patients with systemic inflammatory diseases and acute organ failure.[1][4] The company's core innovation centers on its flagship SBI-101 product, which uses an extracorporeal device to immobilize mesenchymal stromal cells (MSCs) and deliver sustained, controlled doses of anti-inflammatory and regenerative factors.[1][2]
The company serves patients with high-mortality conditions where treatment options are limited, including sepsis-induced acute kidney injury (sepsis-AKI) and polytrauma-induced multiple organ dysfunction.[1][5] Sentien's approach solves a critical problem in cell therapy: traditional direct injection or intravenous infusion methods cannot achieve the therapeutic dosage levels that their immobilization technology enables.[1][2]
Sentien operates within the expanding regenerative medicine sector, where cell therapies are increasingly recognized as transformative treatments for immune-mediated and inflammatory diseases. The company's immobilization technology represents an advancement in addressing a fundamental challenge in cell therapy—achieving therapeutic efficacy through controlled, sustained delivery rather than bolus administration. This positions Sentien within a broader trend of engineering-driven solutions to biological problems, where device-cell combinations create new therapeutic possibilities.
Sentien's trajectory depends on successful clinical validation of SBI-101 in sepsis-AKI and potential expansion to other critical care indications. As the cell therapy market matures and regulatory pathways become clearer, companies demonstrating both clinical efficacy and manufacturing scalability will likely attract significant investment and partnership interest. Sentien's focus on high-mortality conditions with limited alternatives positions it favorably within this competitive landscape, though the path to commercialization in cell therapy remains capital-intensive and lengthy.